Cargando…

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10

BACKGROUND: The human epidermal growth factor receptor (EGFR) is an important therapeutic target in oncology, and three different types of EGFR inhibitors have been approved for the treatment of cancer patients. However, there has been no clear association between the expression levels of EGFR prote...

Descripción completa

Detalles Bibliográficos
Autores principales:	Modjtahedi, H, Khelwatty, S A, Kirk, R S, Seddon, A M, Essapen, S, Del Vecchio, C A, Wong, A J, Eccles, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305949/ https://www.ncbi.nlm.nih.gov/pubmed/22315050 http://dx.doi.org/10.1038/bjc.2012.27

Ejemplares similares

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer
por: Khelwatty, Said Abdullah, et al.
Publicado: (2019)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer
por: Puvanenthiran, Soozana, et al.
Publicado: (2018)

Is membranous location of EGFR or EGFRvIII immunostaining associated with good prognosis in renal cell carcinoma?
por: Modjtahedi, H, et al.
Publicado: (2005)

The natural history of EGFR and EGFRvIII in glioblastoma patients
por: Heimberger, Amy B, et al.
Publicado: (2005)

Will EGFRvIII and neuronal-derived EGFR be targets for imipramine?
por: Li, Zesheng, et al.
Publicado: (2023)

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
por: Padfield, Emily, et al.
Publicado: (2015)

The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer
por: Khelwatty, Said, et al.
Publicado: (2016)

EGFRvIII: the promiscuous mutation
por: Greenall, Sameer A, et al.
Publicado: (2016)

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.
por: Modjtahedi, H., et al.
Publicado: (1996)

Epidermal growth factor receptor (EGFR) and EGFRvIII in glioblastoma (GBM): signaling pathways and targeted therapies
por: An, Zhenyi, et al.
Publicado: (2018)

Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition
por: Shen, Ying, et al.
Publicado: (2015)

EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery
por: Bao, Xuhui, et al.
Publicado: (2016)

EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment
por: Keller, Stefanie, et al.
Publicado: (2017)

Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts
por: Liu, Xujie, et al.
Publicado: (2016)

EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: A potential mechanism of EGFR-driven antagonism of apoptosis
por: Cao, Xinyu, et al.
Publicado: (2011)

Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy
por: Oppenheim, D E, et al.
Publicado: (2014)

Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma
por: Fontanilles, Maxime, et al.
Publicado: (2020)

Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies
por: Ellwanger, Kristina, et al.
Publicado: (2017)

Efficacy of osimertinib against EGFRvIII+ glioblastoma
por: Chagoya, Gustavo, et al.
Publicado: (2020)

Comparison of commonly used ICR stocks and the characterization of Korl:ICR
por: Shin, Hye-Jun, et al.
Publicado: (2017)

Development of an EGFRvIII specific recombinant antibody
por: Gupta, Puja, et al.
Publicado: (2010)

Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies
por: Tuzmen, Ceren, et al.
Publicado: (2020)

Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII(+)PTEN(−) glioblastoma in vivo
por: Xu, Wen, et al.
Publicado: (2016)

EGFRvIII TandAbs are specific and highly potent drug candidates for the treatment of solid tumors
por: Ellwanger, Kristina, et al.
Publicado: (2015)

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models
por: Keir, Stephen T., et al.
Publicado: (2018)

Targeting FHL2 for EGFRvIII-positive glioblastoma
por: Sun, Lili, et al.
Publicado: (2018)

EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma
por: Taher, Mohiuddin M., et al.
Publicado: (2020)

Synergistic antitumor efficacy against the EGFRvIII(+)HER2(+) breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12
por: Xu, Wen, et al.
Publicado: (2015)

The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis
por: Hoogstrate, Youri, et al.
Publicado: (2021)

Multifunctional Nanopolymers for Blood–Brain Barrier Delivery and Inhibition of Glioblastoma Growth through EGFR/EGFRvIII, c-Myc, and PD-1
por: Patil, Rameshwar, et al.
Publicado: (2021)

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
por: Han, Jianfeng, et al.
Publicado: (2015)

Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma
por: Sahin, Ayguen, et al.
Publicado: (2018)

Selective ICR Heating of Lanthanide Plasma
por: Karlin, B E, et al.
Publicado: (2001)

ICRE : Índice de Cumplimiento de la Responsabilidad Educativa : estatal 2018 /
Publicado: (2018)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
por: Khelwatty, Said A., et al.
Publicado: (2021)

Pre-clinical validation of a humanized anti-EGFR variant III chimeric antigen receptor and phase I trial of CART-EGFRvIII in glioblastoma
por: Johnson, Laura A, et al.
Publicado: (2014)

Are Mutations of the EGFR Gene Promising Predictive Markers for Anti-EGFR mAbs in Colorectal Carcinomas?
por: Park, Dong-Guk
Publicado: (2011)

Phenotypical Flexibility of the EGFRvIII-Positive Glioblastoma Cell Line and the Multidirectional Influence of TGFβ and EGF on These Cells—EGFRvIII Appears as a Weak Oncogene
por: Włodarczyk, Aneta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g8ud282q89pdvk17e25n6p9jef